Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma

被引：1

作者：

Lipschitz, Noga ^{[1
]}

Earl, Brian R. ^{[1
,2
]}

Cripe, Timothy P. ^{[3
,4
]}

Samy, Ravi N. ^{[1
,5
,6
]}

机构：

[1] Univ Cincinnati, Coll Med, Dept Otolaryngol Head & Neck Surg, Cincinnati, OH USA

[2] Univ Cincinnati, Dept Commun Sci & Disorders, Coll Allied Hlth Sci, Cincinnati, OH USA

[3] Nationwide Childrens Hosp, Dept Pediat, Div Hematol Oncol Blood & Marrow Transplant, Columbus, OH USA

[4] Nationwide Childrens Hosp, Ctr Childhood Canc & Blood Dis, Res Inst, Columbus, OH USA

[5] Univ Cincinnati, Neurosensory Disorders Ctr, Gardner Neurosci Inst, 213 Albert Sabin Way,MSB 6407, Cincinnati, OH 45267 USA

[6] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA

来源：

CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY | 2020年 / 28卷 / 05期

关键词：

cholesteatoma; herpes simplex virus; oncolytic virotherapy; TALIMOGENE LAHERPAREPVEC; ACQUIRED CHOLESTEATOMA; VIRUS; SAFETY; ADENOVIRUS; MELANOMA; EFFICACY; PATHOGENESIS; COMBINATION; HSV-1;

D O I：

10.1097/MOO.0000000000000651

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Purpose of review To review the principles of oncolytic virotherapy and summarize the recent preliminary evidence on the efficacy of oncolytic virotherapy for cholesteatoma (CHST) treatmentin vitroin human CHST cells and in a gerbil CHST model. Recent findings The use of oncolytic virotherapy for nonmalignant lesions is innovative. In-vitro results showed that oncolytic herpes simplex virus 1 (oHSV) selectively targets and kills CHST cells. In a gerbil model of CHST, local oHSV injections were associated with a decrease in CHST volume and modulation of bony changes. Surgical treatment options for CHST are limited by high morbidity and recidivism, emphasizing the need for developing treatment alternatives. Preliminary results support the potential therapeutic effect of oncolytic virotherapy on CHST, yet further research is needed to evaluate this novel approach.

引用

页码：281 / 285

页数：5

共 50 条

[41] Promising OS with oncolytic virotherapy
David Killock
Nature Reviews Clinical Oncology, 2022, 19 : 616 - 616
[42] Oncolytic Virotherapy in Glioma Tumors
Rius-Rocabert, Sergio
Garcia-Romero, Noemi
Garcia, Antonia
Ayuso-Sacido, Angel
Nistal-Villan, Estanislao
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (20) : 1 - 32
[43] Oncolytic virotherapy for multiple myeloma
Stief, Amaalia E.
McCart, J. Andrea
EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (04) : 463 - 473
[44] Promising OS with oncolytic virotherapy
Killock, David
NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (10) : 616 - 616
[45] Oncolytic virotherapy of breast cancer
Hartkopf, Andreas D.
Fehm, Tanja
Wallwiener, Diethelm
Lauer, Ulrich M.
GYNECOLOGIC ONCOLOGY, 2011, 123 (01) : 164 - 171
[46] Oncolytic virotherapy of glioblastoma: an overview
Rommelaere, Jean
HUMAN GENE THERAPY, 2011, 22 (06) : A7 - A7
[47] Oncolytic Virotherapy Reaches Adolescence
Hammill, Adrienne M.
Conner, Joseph
Cripe, Timothy P.
PEDIATRIC BLOOD & CANCER, 2010, 55 (07) : 1253 - 1263
[48] Oncolytic virotherapy for urological cancers
Delwar, Zahid
Zhang, Kaixin
Rennie, Paul S.
Jia, William
NATURE REVIEWS UROLOGY, 2016, 13 (06) : 334 - 352
[49] Oncolytic virotherapy of gynecologic malignancies
Hartkopf, Andreas D.
Fehm, Tanja
Wallwiener, Diethelm
Lauer, Ulrich
GYNECOLOGIC ONCOLOGY, 2011, 120 (02) : 302 - 310
[50] Syncytia Formation in Oncolytic Virotherapy
Burton, Chase
Bartee, Eric
MOLECULAR THERAPY-ONCOLYTICS, 2019, 15 : 131 - 139

← 1 2 3 4 5 →